DelistingJul 24, 2026, 05:01 PM
Liminatus Pharma Faces Nasdaq Delisting Over Bid Price Rule
AI Summary
Liminatus Pharma received a notice from Nasdaq on July 20, 2026, indicating it has not regained compliance with the $1 minimum bid price rule and is not eligible for a second 180-day extension. The Nasdaq Hearings Panel will now consider the company's continued listing. The company plans to submit a written response to the Panel by July 27, 2026, and previously filed a proxy statement to authorize a reverse stock split.
Key Highlights
- Received notice on July 20, 2026, from Nasdaq regarding non-compliance with the $1 minimum bid price rule.
- Not eligible for a second 180-day extension to regain compliance with the Bid Price Rule.
- Nasdaq Hearings Panel will consider the company's continued listing on Nasdaq.
- Company must present its view to the Panel in writing by July 27, 2026.
- Filed a definitive proxy statement on July 13, 2026, to authorize a reverse stock split.
- Original non-compliance notice received on January 15, 2026, with a compliance period until July 14, 2026.
Price Impact
More from LIMN